Literature DB >> 12802836

Heart failure: an overview of consensus guidelines and nursing implications.

Anna Svendsen.   

Abstract

Heart failure affects more than 350,000 Canadians and costs over $1 billion annually for inpatient care alone. Consensus guidelines have been developed to guide care and improve quality of life based on current evidence or best practice. This article will provide a brief overview of medications and lifestyle modifications described in guidelines developed by the American College of Cardiology/American Heart Association, the Canadian Cardiovascular Society, the Heart Failure Society of America, and the European Society of Cardiology. Medications for treating heart failure can be divided into two groups: those with a mortality benefit (angiotensin converting enzyme inhibitor, beta-blockers, and selective aldosterone receptor antagonists), and those that improve symptoms (diuretics and cardiac glycosides). Nursing implications include careful assessment of volume status, vital signs, monitoring electrolyte and renal function, as well as spacing of medications. Nurses play a key role in assisting patients to identify their lifestyle habits that require modifications, ultimately improving their quality of life and decreasing hospital readmissions. Education focusing on self-care activities, diet, rest, and exercise enables patients to retain a sense of control in their lives.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802836

Source DB:  PubMed          Journal:  Can J Cardiovasc Nurs        ISSN: 0843-6096


  2 in total

1.  Etiological Peculiarities in Pediatric Heart Failure.

Authors:  Angela Butnariu; Gabriel Samasca
Journal:  Maedica (Bucur)       Date:  2015-09

2.  Effect of standard versus patient-targeted in-patient education on patients' anxiety about self-care after discharge from cardiovascular surgery clinics.

Authors:  Tülin Yildiz; Selami Gürkan; Özcan Gür; Cüneyt Ünsal; Sonay Baltacı Göktaş; Yücel Özen
Journal:  Cardiovasc J Afr       Date:  2014-10-29       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.